DelveInsight’s Metastatic Melanoma Pipeline Insight, 2022 report provides comprehensive insights into over 75 companies and over 75 pipeline medicines in the metastatic melanoma pipeline landscape. It covers the pipeline drug profiles, including both clinical and non-clinical stage products. It also includes therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.

Key Findings from the Metastatic Melanoma Pipeline Report

• DelveInsight’s Metastatic Melanoma Pipeline Report shows a robust space with more than 75 active players working towards the development of more than 75 pipeline therapies for the treatment of metastatic melanoma.
• Leading metastatic melanoma companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar Therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen SpA, Ascentage Pharma, Exelixis/ Ipsen, NovoCure Ltd., Hoffman-La-Roche and others are developing new drugs for metastatic melanoma to improve the treatment landscape.
• Major pipeline therapies for metastatic nelanoma at various stages of development include EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, HBI-8000, NKTR-214, CMP-001 , IO102 -IO103, EVX-01, APX005M, BCD-217, Dostarlimab, LXH254, Niraparib, BNT111, UV1, YH003, Retifanlimab, L19IL2+L19TNF, Pexa-Vec, APG-115, Cabozantinib, RO7247669, PV-10, BGB324 , VB10 .NEO, IMO-2125, ABI-007, HX008, BVD-523, IOV-4001, ST101, BGB-10188, DYP688, ATL001, PAC-1, IN10018, SX-682, TILT-123, PV-001 -DC , CDX-301, TBX-3400, GR-MD-02, FHD-286, SD-101, MB-CART20.1, BMS-986249, SEA-CD40, LAG525, Fianlimab,…